Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Ridgeback Biotherapeutics by Year
Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Current receivables from partner ($M) ($M)
Merck Ridgeback Biotherapeutics: $27M in FY2025.
Latest, FY2025
27
Period ended Dec 31, 2025
Change on a year earlier
–
0 in FY2024
History
3 years
Since FY2023
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Current receivables from partner ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27 | – | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 0 | – | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-Q (filed 2024-08-05) ↗ |
Cite this data
StockData. (2026). Merck Ridgeback Biotherapeutics ($M), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-ridgeback-ar-cur
See every metric in the Merck KPI table. Data updated Oct 26, 2026.